Products for Research Use Only
RegisterLogin

Sevabertinib

CAT: 0804-HY-164718-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-164718-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Sevabertinib (BAY 2927088) is an orally active and reversible dual EGFR-HER2 inhibitor (IC50 [1][2].
CAS Number
2521285-05-0
Product Name Alternative
BAY 2927088
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sevabertinib.html
Purity
99.90
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NCC1)C2=C1NC(C3=CC=NC=C3OC[C@@H]4COCCO4)=C2NC5=C(C(Cl)=CC=C5)OC
Molecular Formula
C24H25ClN4O5
Molecular Weight
484.93
References & Citations
[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 38, No. 2, 2024.|[2]Siegel F, et al. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer Discov. 2025 Oct 15.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Chemical Information

Sevabertinib

Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR). It was granted accelerated approval by the FDA on November 19th, 2025.

CAS Number2521285-05-0
PubChem CID155234713
IUPAC Name3-(3-chloro-2-methoxyanilino)-2-[3-[[(2S)-1,4-dioxan-2-yl]methoxy]-4-pyridinyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
Molecular FormulaC24H25ClN4O5
Molecular Weight484.9
XLogP2.9
Topological Polar Surface Area107
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count7
Rotatable Bond Count7
Heavy Atom Count34
Formal Charge0
Complexity690
SMILES
COC1=C(C=CC=C1Cl)NC2=C(NC3=C2C(=O)NCC3)C4=C(C=NC=C4)OC[C@@H]5COCCO5
InChI
InChI=1S/C24H25ClN4O5/c1-31-23-16(25)3-2-4-18(23)29-22-20-17(6-8-27-24(20)30)28-21(22)15-5-7-26-11-19(15)34-13-14-12-32-9-10-33-14/h2-5,7,11,14,28-29H,6,8-10,12-13H2,1H3,(H,27,30)/t14-/m0/s1
InChIKey
VYQVHWNNPKOJEA-AWEZNQCLSA-N
Chemical Structure
2D Structure
2D structure of Sevabertinib
CAS: 2521285-05-0
CID: 155234713
Formula: C24H25ClN4O5
MW: 484.9
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight484.9
XLogP32.9
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count7
Rotatable Bond Count7
Exact Mass484.1513476
Monoisotopic Mass484.1513476
Topological Polar Surface Area107 Ų
Heavy Atom Count34
Formal Charge0
Complexity690
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
BUP20906-01Sevabertinib
E4997-1gBAY 2927088 (Sevabertinib)

Popular Products